Minimum number of responses suggested to achieve moderate or highly improved responses compared with azacitidine monotherapy
No. of patients* . | Moderately improved over DNMTI monotherapy . | Highly improved over DNMTI monotherapy . | Expected DNMTI outcomes . | ||||||
---|---|---|---|---|---|---|---|---|---|
Goal response | CR | CR+PR+mCR | HI | CR | CR+PR+mCR | HI | CR | CR+PR+mCR | HI |
Alpha = 0.05 | 30% | 50% | 60% | 50% | 70% | 75% | 14% | 24% | 30% |
10 | 7 | 9 | 10 | 9 | 10 | – | |||
15 | 9 | 12 | 13 | 12 | 15 | 15 | |||
20 | 11 | 15 | 17 | 15 | 19 | 19 | |||
25 | 13 | 18 | 20 | 18 | 23 | 24 | |||
30 | 15 | 21 | 24 | 21 | 26 | 28 | |||
35 | 17 | 24 | 27 | 24 | 30 | 32 | |||
40 | 19 | 27 | 31 | 27 | 34 | 36 | |||
45 | 20 | 30 | 34 | 30 | 38 | 40 | |||
50 | 22 | 33 | 37 | 33 | 42 | 44 | |||
55 | 24 | 36 | 41 | 36 | 46 | 48 | |||
60 | 26 | 39 | 44 | 39 | 49 | 52 | |||
65 | 27 | 41 | 47 | 41 | 53 | 56 | |||
70 | 29 | 44 | 51 | 44 | 57 | 60 | |||
75 | 30 | 47 | 54 | 47 | 61 | 64 | |||
80 | 33 | 50 | 57 | 50 | 65 | 68 | |||
Goal response | CR | CR+PR+mCR | HI | CR | CR+PR+mCR | HI | CR | CR+PR+mCR | HI |
Alpha = 0.10 | 30% | 50% | 60% | 50% | 70% | 75% | 14% | 24% | 30% |
10 | 6 | 9 | 9 | 9 | 10 | 10 | |||
15 | 12 | 12 | 13 | 12 | 14 | 15 | |||
20 | 10 | 15 | 16 | 15 | 18 | 19 | |||
25 | 12 | 18 | 20 | 18 | 22 | 23 | |||
30 | 14 | 20 | 23 | 20 | 26 | 27 | |||
35 | 16 | 23 | 27 | 23 | 30 | 31 | |||
40 | 17 | 26 | 30 | 26 | 34 | 35 | |||
45 | 20 | 29 | 33 | 29 | 37 | 39 | |||
50 | 21 | 32 | 37 | 32 | 41 | 43 | |||
55 | 23 | 35 | 40 | 35 | 45 | 47 | |||
60 | 24 | 37 | 43 | 37 | 49 | 51 | |||
65 | 25 | 40 | 46 | 40 | 52 | 55 | |||
70 | 27 | 43 | 50 | 43 | 56 | 59 | |||
75 | 28 | 46 | 53 | 46 | 60 | 63 | |||
80 | 31 | 48 | 56 | 48 | 64 | 67 |
No. of patients* . | Moderately improved over DNMTI monotherapy . | Highly improved over DNMTI monotherapy . | Expected DNMTI outcomes . | ||||||
---|---|---|---|---|---|---|---|---|---|
Goal response | CR | CR+PR+mCR | HI | CR | CR+PR+mCR | HI | CR | CR+PR+mCR | HI |
Alpha = 0.05 | 30% | 50% | 60% | 50% | 70% | 75% | 14% | 24% | 30% |
10 | 7 | 9 | 10 | 9 | 10 | – | |||
15 | 9 | 12 | 13 | 12 | 15 | 15 | |||
20 | 11 | 15 | 17 | 15 | 19 | 19 | |||
25 | 13 | 18 | 20 | 18 | 23 | 24 | |||
30 | 15 | 21 | 24 | 21 | 26 | 28 | |||
35 | 17 | 24 | 27 | 24 | 30 | 32 | |||
40 | 19 | 27 | 31 | 27 | 34 | 36 | |||
45 | 20 | 30 | 34 | 30 | 38 | 40 | |||
50 | 22 | 33 | 37 | 33 | 42 | 44 | |||
55 | 24 | 36 | 41 | 36 | 46 | 48 | |||
60 | 26 | 39 | 44 | 39 | 49 | 52 | |||
65 | 27 | 41 | 47 | 41 | 53 | 56 | |||
70 | 29 | 44 | 51 | 44 | 57 | 60 | |||
75 | 30 | 47 | 54 | 47 | 61 | 64 | |||
80 | 33 | 50 | 57 | 50 | 65 | 68 | |||
Goal response | CR | CR+PR+mCR | HI | CR | CR+PR+mCR | HI | CR | CR+PR+mCR | HI |
Alpha = 0.10 | 30% | 50% | 60% | 50% | 70% | 75% | 14% | 24% | 30% |
10 | 6 | 9 | 9 | 9 | 10 | 10 | |||
15 | 12 | 12 | 13 | 12 | 14 | 15 | |||
20 | 10 | 15 | 16 | 15 | 18 | 19 | |||
25 | 12 | 18 | 20 | 18 | 22 | 23 | |||
30 | 14 | 20 | 23 | 20 | 26 | 27 | |||
35 | 16 | 23 | 27 | 23 | 30 | 31 | |||
40 | 17 | 26 | 30 | 26 | 34 | 35 | |||
45 | 20 | 29 | 33 | 29 | 37 | 39 | |||
50 | 21 | 32 | 37 | 32 | 41 | 43 | |||
55 | 23 | 35 | 40 | 35 | 45 | 47 | |||
60 | 24 | 37 | 43 | 37 | 49 | 51 | |||
65 | 25 | 40 | 46 | 40 | 52 | 55 | |||
70 | 27 | 43 | 50 | 43 | 56 | 59 | |||
75 | 28 | 46 | 53 | 46 | 60 | 63 | |||
80 | 31 | 48 | 56 | 48 | 64 | 67 |
Minimum event size calculation is based on CR rate in that group and the sample size, ranging from 10 to 80 patients, and with alphas of 0.05 (top) and 0.10 (bottom).